Medical Writing Services – EU & UK Regulatory Documentation for Medicinal, Veterinary, Herbal & Cosmetic Products

Complete preparation, review, and optimisation of regulatory documents and scientific reports for human and veterinary medicinal products, traditional herbal medicines, and cosmetic products in Europe and the United Kingdom. Our medical writing team produces clear, compliant documentation from clinical overviews and quality summaries to safety assessments and authority response letters  ensuring every document meets EMA, MHRA, and other regulator expectations. Our writers have extensive experience and expertise in the quality, non-clinical and clinical regulatory aspects of product development, enabling us to translate complex data into submission-ready dossiers that stand up to inspection.

• Pharmaceutical & Biotech Companies (Human Medicines): Small to mid-sized innovators or generic drug manufacturers who lack an in-house medical writing team or whose staff are at capacity. If you need to prepare Common Technical Document (CTD) modules (Quality, Non-clinical, Clinical) or other regulatory reports for EU or UK submissions and want them done right the first time, we provide the expertise. This includes authorship of Quality Overviews, Non-clinical Overviews, Non-clinical Summaries, Clinical Overviews all document types listed among our core offerings as well as drafting patient-facing documents like SmPCs (Summary of Product Characteristics), labelling, and Patient Information Leaflets (PILs) in line with EU templates.
• Veterinary Health Product Sponsors: Companies developing veterinary medicinal products (for companion animals or livestock) who must compile a complete dossier under Regulation (EU) 2019/6 and UK VMD requirements. We cater to MAHs pursuing centralised (CVMP) approvals, decentralised or mutual recognition procedures, or national veterinary licences. Our service addresses the unique writing needs of veterinary dossiers  from target animal safety and Environmental Risk Assessments (ERAs) to residue study summaries for food-producing animals ensuring compliance with VICH guidelines and veterinary-specific standards.
• Herbal Medicine Producers: Firms registering well-established use or traditional herbal medicinal products under simplified schemes. Directive 2004/24/EC on traditional herbal medicinal products requires a company to show the quality, safety and efficacy of their herbal medicinal products by demonstrating traditional use within the EU for at least 15 years and at least 30 years outside the EU. The herbal medicines can be approved for marketing either through a Traditional Herbal Registration (THR) or a Marketing Authorisation registration (MA). We assist by authoring the required expert overviews and summaries that collate this evidence, and by writing CTD Modules 1–5 adapted to herbal products  including construction of Module 1 (SmPC, product labelling and PIL texts), performance of Readability User Testing, generation of Braille, and construction and writing of CTD Modules 2, 3, 4 and 5.
• Cosmetics & Personal Care Companies: Manufacturers or Responsible Persons placing cosmetic products on the EU/UK market who need to compile Product Information Files (PIFs) and draft Cosmetic Product Safety Reports (CPSRs). The regulatory framework for cosmetic products is provided by the European Cosmetics Regulation 1223/2009, which reinforces the link between the product information file, the product safety report and the cosmetic safety assessment and places greater responsibilities on the Responsible Person and the safety assessor. Our service provides the scientific writing support to prepare safety assessments of finished products based on the toxicological profile of the ingredients. We also support related documentation such as notification to competent authorities, declarations to poison centres, compiling labelling requirements, and substantiating claims.
• Established MAHs with Documentation Bottlenecks: Larger organisations with internal regulatory or pharmacovigilance teams that occasionally require surge capacity or specialist support. For example, you may handle routine documents in-house but need external support for an upcoming complex dossier, a series of Periodic Safety Update Reports, or a one-off paediatric investigation plan. Our writers are familiar with a broad range of product types and regulatory pathways and can slot in to manage documentation for a one-time project or on an ongoing retainer.

This service may not be the right fit if:

• You need clinical trial medical writing (protocols, investigator brochures) as a standalone service. We can advise on integrating clinical study reports into registrations, but full clinical trial document authoring is not our primary offering unless in the context of a broader regulatory submission project.

• Condensing Complex Data into Regulator-Friendly Formats: Turning reams of scientific data (from CMC development, toxicology studies, clinical trials) into the concise CTD Module 2 summaries and overviews that regulators expect. Many companies struggle to distil key findings or to avoid overly promotional language. We write authoritative yet succinct summaries that highlight a product’s quality, safety, and efficacy, while strictly following the format defined in guidelines. The Quality Overall Summary (QOS), for example, should be prepared according to the provisions described in the Notice to Applicants for Medicinal Products for human use (Volume 2B – CTD Module 2.3). The result is a set of documents that tell your product’s story clearly and withstand detailed scrutiny.
• Ensuring Consistency Across Documents: In a typical marketing authorisation dossier, the same information might appear in multiple places (for example, a serious adverse reaction might be detailed in a clinical study report in Module 5, summarised in the Clinical Overview in Module 2, and listed in the SmPC). Inconsistencies or transcription errors between the main data and summary documents are red flags for reviewers and can lead to avoidable questions. We implement rigorous cross-checking: our writers work closely with your subject matter experts and use quality control checklists to align every claim, table, and statistic in an overview with the source data in Modules 3–5.
• Staying Current with Evolving Guidelines: Regulatory documentation standards evolve with new guidelines and assessment trends. From the latest ICH template updates to new EMA guidance on benefit–risk assessment, it is easy for companies to unknowingly use outdated formats or miss newly emphasised content. We continuously monitor regulatory guidance and assessor feedback. For instance, we ensure your Quality Overall Summary addresses current expectations, and that your Clinical Overview includes a robust discussion of safety concerns and how they will be managed  a common focus of today’s CHMP and PRAC assessments. The EMA’s step-by-step evaluation process explicitly includes assessment of the company’s proposed risk management plan (RMP), which describes the way important risks will be minimised or managed if the medicine is authorised and how more information will be obtained about the medicine’s risks and uncertainties.
• Bridging Data Gaps and Justifying Approaches: Especially for generic products, biosimilars, or products with atypical development programmes, a key writing challenge is explaining how your data supports approval when there are gaps or scientific complexities. For traditional herbal registrations, an expert report must justify efficacy purely from published evidence and historical use specifically, demonstrating at least 15 years of medicinal use in the EU and 30 years globally. We help craft persuasive justifications for regulatory acceptance, referencing guidelines and precedents to support your approach.
• Multi-Jurisdictional Coordination Post-Brexit: If you plan to submit in both the EU and the UK, you face duplicative documentation with subtle differences. We ensure that while you maintain one core set of documents, any UK-specific requirements are appropriately addressed without contradicting the EU dossier. Similarly, we can prepare both EU and GB versions of product information texts (e.g. SmPCs) to account for diverging reference product names or local administrative details.
• Resource & Time Constraints in Document Preparation: Preparing a high-quality dossier or safety report is time-consuming. Companies often underestimate the time needed for writing and internal review, leading to last-minute pressure that compromises quality. We provide additional bandwidth and a structured process. Our involvement allows your subject matter experts to focus on science and data while we handle the writing and formatting.

Regulators like the EMA, MHRA, HPRA, and national competent authorities have clear expectations for the content and quality of regulatory documents:

• Adherence to Standard Formats and Guidelines: Regulatory documents must follow established structures. For human and veterinary medicines, this means the Common Technical Document (CTD) format (or its electronic equivalent, eCTD/VNeeS). Authorities expect a Module 2 that faithfully summarises Modules 3–5 without adding new data. A Quality Overall Summary (QOS) should be prepared according to the Notice to Applicants (Volume 2B, Module 2.3 format), and the QOS should be submitted in PDF format. Similarly, Clinical and Non-clinical Overviews should follow the structure and headings defined by ICH M4E (for efficacy) and M4S (for safety) guidelines. Deviating from these formats or leaving sections blank without justification can result in validation issues or questions.
• Completeness and Accuracy of Data Presentation: Every claim or summary must be backed by data in the dossier, and no required section should be omitted. Regulators will compare your Module 2 summaries against the detailed data in Modules 3 (Quality), 4 (Non-clinical studies), and 5 (Clinical studies) to ensure consistency. They expect the overviews to provide expert interpretation  highlighting crucial findings, explaining the rationale for study designs, and discussing any limitations or deviations. If Modules 2 and 5 show inconsistencies or contradictions, it undermines confidence and triggers queries.
• Clear Benefit–Risk Evaluation: Regulators ultimately base approval on whether benefits outweigh risks. A strong benefit–risk discussion is central to the evaluation process. The EMA’s process explicitly involves PRAC members appointed as rapporteur and co-rapporteur to assess the company’s proposed risk management plan (RMP), which describes the way important risks will be minimised or managed if the medicine is authorised. We ensure this analysis is front and centre in the documents we write, reflecting any risk minimisation measures in the relevant sections. If a product’s risks will be managed by a Risk Management Plan, regulators expect to see consistency between the RMP and the Clinical Overview’s safety discussions.
• Qualified Expert Involvement: In practice, regulators assume that suitably qualified experts have either authored or at least reviewed the key summary documents. EU applications include a requirement to provide information on the experts in Module 1 (typically short CVs or credentials for the experts responsible for Quality, Non-clinical, and Clinical Overviews). Likewise, a cosmetic product’s safety report must be signed off by a qualified safety assessor, as the Cosmetics Regulation places greater responsibilities on the Responsible Person and the safety assessor.
• Evidence of Traditional Use for Special Categories: For a Traditional Herbal Registration (THR), the dossier must demonstrate traditional use within the EU for at least 15 years and at least 30 years outside the EU. In addition, the herbal medicines must now be manufactured under GMP conditions. The Clinical Overview for such a product would need to cite published literature, historical pharmacopoeias, and any pharmacovigilance data from that period to convince regulators of efficacy and safety based on tradition.
• For Cosmetics: Comprehensive Product File: Under Regulation (EC) No 1223/2009, authorities expect a Product Information File that is complete and readily available for inspection. This includes a Cosmetic Product Safety Report with the required safety assessment. Every ingredient must be accounted for with its toxicological profile, every claim must be substantiated, and the final safety conclusion must be unambiguous. Writing safety assessments of finished products based on the toxicological profile of the ingredients is a specialised activity that must meet the standard regulators would expect if they opened your PIF.
• Accuracy and Clarity: Regulators expect honesty and clarity. Any attempt to obscure unfavourable data will likely be spotted and severely undermines trust. Our writing approach is to address issues head-on with factual explanations and proposed solutions or justifications. By clearly stating what was done, what was not done (and why), and how any limitations have been mitigated, we align with the expectation of transparency.

Our delivery model covers the full document lifecycle: from early strategy and gap analysis, through drafting and quality control, to handling updates and questions that arise post-submission.

Every successful document begins with a solid plan. In this initial phase, we partner with your project team (regulatory affairs, R&D scientists, clinical experts) to understand the product and define the document strategy:

• Defining Key Messages & Data Flow: We identify the core messages that need to be conveyed in each document. This often involves a deep dive into your data and brainstorming with your experts. If a product has particular strengths or weaknesses, we plan how to highlight or contextualise them appropriately.
• Document List & Template Setup: We enumerate all documents required for your submission or project  from CTD summaries and Module 1 content (cover letters, application forms, product information) to any special documents like Paediatric Investigation Plans or Orphan Drug designation applications. For each, we either use the official template (e.g. the EDQM provides a Word template for the QOS, which should be converted into a PDF when completed) or our own internal template aligned to guidelines. Setting up templates early ensures consistency in format and helps us and you see the big picture of what information will go where.
• Gathering Regulatory Guidelines & Precedents: We compile all relevant guidance that will inform the writing. For example, for a new chemical entity, we gather the applicable ICH guidelines (M4, E3 for clinical study reports), any EMA or MHRA guidance specific to the therapeutic area, and past assessment reports or public EPARs of similar products. For a herbal product, we would review any HMPC monographs and assessment reports of similar THR products. For cosmetics, we review SCCS opinions on relevant ingredients and Regulation 1223/2009 Annex I requirements.
• Timeline and Review Planning: Based on your target submission date, we work backwards to allocate time for drafting, internal review, your team’s review, and quality control. We establish the review cadence  perhaps chapter-by-chapter reviews or one consolidated review  depending on your preference.

This is the core of our service  the actual writing of documents needed for your submissions or compliance obligations. Our capabilities span virtually all document types involved in human, veterinary, herbal, and cosmetic product regulation:

• CTD Module 2 Summaries & Overviews: We author the crucial quality, non-clinical, and clinical overviews and summaries that form Module 2 of a dossier. These are our core listed deliverables: Provision of Quality Overview, Provision of Non-clinical Overview, Provision of Non-clinical Summary, Provision of Clinical Overview. For Quality Overall Summaries (QOS), our chemists summarise your Module 3 data, emphasising critical quality attributes, manufacturing process validation, and justification of specifications. For Non-Clinical Overviews/Summaries, our pharmacology writers compile the findings from animal studies (pharmacodynamics, pharmacokinetics, toxicology) and, where needed, integrate published literature. The Clinical Overview is written by medically trained writers who provide an integrated analysis of efficacy and safety across all trials and include sections on biopharmaceutics and clinical pharmacology as required.
• Product Information and Labelling Documents: Clear, consistent product information is as important as the dossier itself. We prepare Summary of Product Characteristics (SmPC) documents, Patient Information Leaflets (PIL), and labelling text for human and veterinary medicines. For herbal medicines, we ensure the wording aligns with any relevant HMPC monograph wording or required statements for traditional herbal remedies. For herbal products specifically, we handle construction of Module 1, including writing of the SmPC, product labelling and Patient Information Leaflet (PIL) texts.
• Veterinary Regulatory Documents: For veterinary dossiers, we adapt our writing to the specific requirements of Regulation (EU) 2019/6, addressing target animal safety, consumer safety (for food-producing animals, involving withdrawal periods and residue studies), user safety, and environmental safety considerations. The regulatory format for veterinary submissions is VNeeS (Veterinary Non-eCTD electronic Submission), and we ensure all written content is structured accordingly.
• Herbal Medicinal Product Dossiers: We write CTD Modules 2, 3, 4 and 5 adapted to herbal products. For THR applications, the writing centres on compiling evidence of traditional use and safety based on longstanding experience and bibliographic data. We also support applications for Wholesalers Authorisation (preparation, compilation, submission and project management) and Manufacturer and Importer Authorisations (preparation, compilation, submission).
• Cosmetic Product Documentation: For cosmetics, our writing scope includes authoring the Cosmetic Product Safety Report (CPSR)  specifically the Safety Assessment. We write safety assessments of finished products, based on the toxicological profile of the ingredients. We also prepare and audit Product Information Files (PIF), help with substantiating claims, and ensure compliance with ISO 22716 Cosmetics Good Manufacturing Practices requirements within the documentation. We support the REACH registration process documentation where relevant.
• Reference Product Samples: As part of our broader medical writing and regulatory service, we also support the provision of reference product samples  a sometimes-overlooked element of dossier preparation that is critical for generic or hybrid applications where physical comparison with the reference product is required.

Every document we author goes through our internal quality review. A second senior writer or scientific editor reviews it for accuracy, clarity, and consistency with other documents. We also run checks against regulatory checklists to make sure nothing is overlooked.

Clients often approach us not for writing from scratch, but to review and improve existing documentation:

• Regulatory Compliance Checks: We thoroughly review your draft documents (or previously submitted ones) against current guidelines and regulatory expectations. For example, if you provide a draft Clinical Overview, we check it against the structure recommended by ICH M4E and EMA appraisal trends. We might find that there is no explicit Benefit–Risk Conclusions section (which is expected), or that the Non-clinical Overview has not discussed impurity qualification from a toxicological perspective  gap we would flag and then help fill.
• Data Consistency and Cross-Referencing Audit: We perform a detailed consistency check  does the PIL align with the SmPC? Are numbers (like adverse event incidence rates, or analytical batch numbers) consistent between the study reports and the summaries? We create a matrix of key data points across documents to spot discrepancies quickly.
• Content Gap Identification: Beyond format and consistency, we look for substantive content gaps. Is the justification for not submitting certain studies provided? Did the Clinical Overview fail to mention a known class-effect safety concern? In the veterinary context, have all target species been addressed and is there a discussion on user safety? We compile a list of such gaps and recommend how to address each, often outlining bullet points of what to write, complete with references to source data or guidelines.
• Improving Clarity and Professionalism: We also assess the writing quality itself. Regulatory writing benefits from a neutral, authoritative tone we remove conjecture and ensure every claim is backed by data, using phrasing like “demonstrated a 35% relative risk reduction” rather than “greatly reduced risk.”
• Conformance to Templates and Style: We ensure your documents conform to any required style  correct units, abbreviations lists, document taxonomy matching CTD format, and the latest templates. For herbal THR dossiers, we check that the Herbal Expert Report addresses all points required. For cosmetics, if reviewing a draft CPSR, we verify it contains all sections required by Regulation 1223/2009 Annex I.

At the end of a gap analysis, you receive either a marked-up document with tracked changes and comments, or a Gap Analysis Report listing recommended additions and changes. We can then proceed to implement these improvements, or hand it back for your team to address internally.

Regulatory writing extends to ongoing safety documentation and benefit–risk assessments throughout a product’s life. We prepare a suite of pharmacovigilance and risk management documents, working closely with our Pharmacovigilance Services team when needed:

• Risk Management Plans (RMPs): We author comprehensive RMPs for human medicines and Risk Mitigation Plans for veterinary medicines. Preparing an RMP involves detailing the Safety Specification (important identified risks, important potential risks, missing information), proposing a Pharmacovigilance Plan (e.g. post-authorisation studies or special monitoring), and outlining Risk Minimisation Measures (both routine and additional). The EMA process includes two PRAC members appointed as rapporteur and co-rapporteur to assess the company’s proposed risk management plan, so the RMP is a critical, high-visibility document.
• Periodic Safety Update Reports (PSURs/PBRERs): We prepare PSURs in line with ICH E2C (R2) and GVP Module VII. This includes summarising interval and cumulative safety data, performing analyses of subject exposure, adverse event frequency, and benefit–risk evolution over the period. Our pharmacovigilance team is responsible for preparation, review and reporting/submission of Periodic Safety Update Reports (PSURs) as described within established SOPs, with the QPPV ensuring medical assessment of PSURs takes place where applicable. For veterinary products, we prepare Periodic Safety Update Reports as required under the applicable legislation, including the Veterinary Medicines Regulations 2013 and Volume 9B guidelines.
• Clinical Expert Reports for Renewals or Variations: For products going through renewal (after 5 years in the EU), or significant variations (like adding a new indication), regulators often expect an updated clinical or non-clinical overview reflecting any new information since approval. We prepare these addendum overviews. For example, at a 5-year renewal we write a brief document summarising new safety knowledge gained from marketing experience, referencing PSUR data, and confirming that the benefit–risk remains positive.
• Cosmetovigilance Documentation: If a cosmetic product has a Serious Undesirable Effect (SUE) reported, we help draft the mandatory report to authorities. Notification to competent authorities is among the regulatory services listed for cosmetics, and we ensure these reports are factual and complete, including all details required by Regulation 1223/2009.

Throughout all these safety documents, a key aspect is maintaining consistency between what is said in these and the core product documents (SmPC, etc.). If in a PSUR we conclude a new adverse reaction should be added to the SmPC, we flag this and can help update the labelling through our Regulatory Affairs service in parallel.

Responding to regulatory authorities’ questions is a critical writing task that can make the difference between an approval and a prolonged review:

• Answer Strategy and Drafting: When you receive a list of questions  be it from CHMP (Day 120 List of Questions, or Day 180 List of Outstanding Issues), a set of national authority queries, or questions on a variation or PSUR  our first step is to help strategies the response. Some questions are straightforward requests for information; others may point to a deeper concern. Our writers draft the responses in clear, measured language, directly addressing the point. We structure answers with an introductory sentence that directly answers the question, followed by any necessary explanation or data.
• Data Mining and Additional Analysis: Regulatory questions can require diving back into the data. Our team’s cross-functional nature means we can extract the needed information and even perform minor re-analyses or calculations to support the answer. We ensure any new analysis is consistent with the original dossier format and, if significant, present it as an updated section or appendix.
• Ensuring Timely and Compliant Submission: Regulatory question responses often come with strict deadlines. The assessment of a marketing authorisation application takes up to 210 active days, with clock-stops during which the applicant prepares the answers to any questions raised by the CHMP. The first clock-stop usually lasts three months and the second clock-stop one month. Overall, the assessment of a new medicine usually lasts around a year. The assessment time may be reduced to 150 days instead of 210 days if the medicine developer is granted accelerated assessment, which is possible for medicines considered of major interest for public health. We organise an efficient workflow to meet these deadlines and ensure the format of the response document meets agency preferences.
• Lifecycle Maintenance Writing: Beyond initial approvals, any change to your product might require an update to documentation. We take on writing assignments for Type II variation submissions (for significant changes like a new indication or new manufacturing site). This can involve updating affected CTD sections, writing an Addendum Clinical Overview for a new indication, or updating the Quality Overall Summary for a CMC change.

For many clients, medical writing needs are continuous. We offer ongoing support arrangements that provide continuity and accumulated product knowledge:

• Dedicated Writing Teams: We assign a consistent medical writer (or team) to your company who over time becomes intimately familiar with your products, style preferences, and internal processes. This continuity means faster turnaround and less repeated briefing for each new document.
• Annual or Semi-Annual Document Updates: Some documents benefit from periodic refresh even when not strictly required by regulators. We can maintain an annual updated Clinical Overview  useful for inspections or as a basis for future variations. We can also update pharmacovigilance/clinical sections of the dossier with each PSUR cycle.
• Extension to New Projects: Our team covers human, veterinary, herbal, and cosmetic domains, so you can engage us for writing needs across your portfolio. Having a single provider for all these reduces coordination effort and fosters consistency.
• Continuous Compliance Monitoring: As part of an ongoing engagement, we proactively keep you informed of regulatory changes that might necessitate rewriting or updating documents, ensuring you are never caught off-guard by a suddenly non-compliant format.
• On-site/On-call Support: Some clients opt for our writers to be virtually integrated into their teams. We can attend internal project meetings (remotely or on-site) to stay updated on progress, and we offer on-call support for time-sensitive needs.

Our medical writing services are geared to the requirements of the European Union/EEA and the United Kingdom:

• European Union & EEA (Human Medicines): We prepare documentation for EMA-centralised procedures as well as decentralised (DCP), mutual recognition (MRP), and national MA applications in EU member states. All EU human medicine submissions employ the CTD format. We also cover EEA countries (Norway, Iceland, Liechtenstein) which follow EU rules. Our knowledge extends to subtleties like national requirements in Module 1 and EU-specific documents such as Paediatric Investigation Plans or EU Risk Management Plans assessed by the PRAC.
• United Kingdom (Human Medicines): Post-Brexit, Great Britain has its own marketing authorisation processes. We prepare dossiers for MHRA submissions, which still use CTD format but with some differences (for example, a UK-specific Module 1). We track MHRA guidance to ensure documents remain compliant with any UK-only expectations.
• Veterinary Medicines (EU & UK): For veterinary products, we cover EMA/CVMP centralised procedures and CMDv-coordinated DCP/MRP, as well as national licences. The EU framework since January 2022 is governed by Regulation (EU) 2019/6, and submissions use VNeeS format. We also handle UK VMD applications. When writing vet documents, we pay attention to unique aspects such as Environmental Risk Assessments, Maximum Residue Limit (MRL) justifications for food animals, and the inclusion of a Benefit–Risk Assessment section.
• Herbal Medicinal Products: In the EU/UK, herbal products can be registered via Traditional Herbal Registration (THR) or full Marketing Authorisation routes. Directive 2004/24/EC introduced a pathway for marketing and licensing traditional herbal medicines. We tailor Module 2 documents to reflect either the traditional use pathway (with emphasis on bibliographic and experiential evidence) or well-established use (which requires showing published scientific evidence of efficacy). We can register herbal medicinal products in the UK, Ireland or other EU countries.
• Cosmetics (EU & UK): The EU Cosmetic Products Regulation (EC) No 1223/2009 is applicable EU-wide (and the UK has implemented an equivalent law). Our documentation support for cosmetics covers all EU member states and the UK. If you are the Responsible Person for cosmetics placed in both the EU and UK, you need separate notifications we ensure the written parts (product descriptions, justification of claims) are consistent between both jurisdictions.
• Beyond EU/UK (Reference Use): While our prime focus is EU/UK, we often write documents that can be leveraged for other regions. CTD summaries we prepare can often be used in Canada, Switzerland, or Australia with minimal modifications, since those regions also use CTD. If you have global ambitions, our writers can write to the most stringent common standard so that the same dossier content satisfies multiple regions’ requirements.

The time required to produce high-quality regulatory documents varies based on document type, complexity, and data availability. Below is an indication of typical timeframes, assuming necessary data is readily available. These are planning estimates; actual timelines should be confirmed based on project specifics.

(Before publication, these timeline estimates should be reviewed against current internal performance data. We base them on past project experience, but each situation can differ.)

Over the years, we have observed a set of recurrent pitfalls in regulatory document preparation. Our process is designed to sidestep these:

• Omitting Required Content or Sections: One of the simplest errors is leaving out a section because it seems not applicable, without providing a justification. We ensure every single section that is expected by guidelines is either completed with relevant content or marked as not applicable with a brief justification. This pre-empts the regulators’ need to question the omission.
• Inconsistent Data Presentation: Mismatch of numbers across documents  say, the number of patients exposed in clinical trials is 823 in one section and 825 in another is a top reason regulator lose confidence in submissions. Such inconsistencies creep in when documents are authored by separate teams or updated at different times. Our integrated writing approach and thorough cross-checking prevent this. We also align language between documents: if the SmPC calls an adverse event “common” (≥1/100), the Clinical Overview uses the same terminology.
• Poor Justification of Deviations or Unusual Aspects: A common mistake is either to ignore deviations from guidelines or to mention them without a persuasive justification. For every known deviation, we craft a clear justification grounded in science or precedent. By addressing these proactively in the dossier, we often prevent them from becoming questions later.
• Overt or Covert Promotional Tone: Regulatory documents must be scientific and neutral. Phrases like “groundbreaking efficacy” or “completely safe” have no place they irritate assessors and diminish credibility. We maintain an objective tone, presenting results and letting the numbers speak.
• Inadequate Quality Control and Formatting Errors: Wrong line spacing in the SmPC, tables breaking across pages, inconsistent font usage, or numerous typos signal a lack of care. Before any document goes out, we run spell check (in UK English), verify all references, confirm table and figure numbering, and ensure formatting follows the required style.
• Lack of Alignment with Regulatory Guidelines: Sometimes companies write documents based only on internal knowledge without realising they are misaligned with guidelines. We always cross-check content against relevant guidelines and checklists used by regulators to ensure nothing expected is absent.
• Neglecting to Address the Benefit–Risk Evaluation Properly: The EMA evaluation process involves detailed review of the benefit–risk profile, including assessment by PRAC rapporteurs of the risk management plan. A Clinical Overview that focuses heavily on efficacy while paying scant attention to safety will attract questions. We ensure balanced, critical analysis of the product’s benefit–risk profile across all relevant documents.

Delivering top-notch documents often intersects with other regulatory and compliance activities. We provide a suite of services that complement Medical Writing:

Regulatory Affairs Management: Our medical writing is closely integrated with our Regulatory Affairs Management service. While we draft your dossier, our regulatory affairs consultants can simultaneously handle agency interactions, submission logistics, and strategy. If the medical writing uncovers a need for additional data or a regulatory workaround, our RA team assists directly.

Pharmacovigilance Services: Documents like RMPs, PSURs, and safety sections of dossiers draw directly from pharmacovigilance data. Our Pharmacovigilance Services team can set up and manage your safety system, providing the raw data and analyses that our writers incorporate into reports. Our pharmacovigilance SOPs reference both EU GVP Module VII and MHRA Good Pharmacovigilance Practices (GVP) Guidelines. The close collaboration ensures that the content of your safety documents is not only well-written but also fully compliant with PV requirements.

Readability User Testing & PIL Services: Writing a Patient Information Leaflet (PIL) is one task — ensuring it is patient-friendly and tested is another. We offer Readability User Testing for PILs (as required by EU directive for new medicines). For herbal products, performance of Readability User Testing is a listed service. We design and conduct the testing with target readers, analyse the results, and provide the Readability Test Report. This dovetails with medical writing: we draft the PIL text and then validate it through testing.

eCTD Publishing & Submission: Once the documents are written, they must be compiled in the electronic Common Technical Document (eCTD) format for submission. Our team uses docuBridge to publish eCTD sequences. Because our medical writers work closely with our publishing specialists, we ensure that documents are eCTD-ready (bookmarked, navigable, correctly named). We can compile the entire application Module 1 through 5  into an eCTD and submit it via the EMA Gateway or CESP.

Quality and GMP Compliance Consulting: Especially for CMC sections of dossiers and related documents, our Quality Services unit can provide the necessary technical input or even full authoring of Module 3. If during writing we identify a gap in a validation report, our GMP consultants step in to assist.

Cosmetics Regulatory Support: Beyond safety assessment writing, our cosmetics service covers notification to the competent authorities, declarations to poison centres, compiling the labelling requirements, and ensuring compliance with ISO 22716 Cosmetics Good Manufacturing Practices. This broader support ensures the PIF and all accompanying regulatory actions are handled coherently.

Herbal Products Regulatory Support: For herbal medicinal products, we offer a complete regulatory package  from construction and writing of CTD Modules 2, 3, 4 and 5 to Wholesalers Authorisation and Manufacturer and Importer Authorisations preparation, compilation, and submission. Combined with Braille generation and labelling work, this gives herbal clients end-to-end support.

Regulatory Outsourcing: If you find you have a long-term need, we can provide experienced medical writers on a contract basis to function as part of your team. This falls under our outsourcing services. We handle the management; you get the dedicated resource.